

## Amniotics AB announces positive pre-clinical proof-of-concept results for PulmoStem™ in end-stage lung disease

**Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that PulmoStem™ significantly reduces the incidence of Primary Graft Dysfunction (PGD) in a pre-clinical study of lung transplantation, which is the definitive treatment of patients with end-stage lung disease. The positive effects of the treatment with PulmoStem™ were presented at the International Society for Heart and Lung Transplantation (ISHLT) 42nd Annual Meeting & Scientific Sessions, which is being held on the 27-30th of April in Boston, US.**

Dr. A. Niroomand, from the Lindstedt group at Lund University and Skåne University Hospital in Sweden presented results from the lung transplantation study using Acute Lung Injury (ALI)-damaged donor lungs. The data showed that following the administration of the company's biological therapy PulmoStem™, the injured lungs were recovered to be suitable for transplantation. This is important as the donor utilization rate is cited to be as low as 20 to 50% and PulmoStem™ has the potential to increase the pool of donor lungs. In addition, the incidence of PGD, a severe complication, after the transplantation, was significantly reduced, whereas the non-treated lungs all had significant lung injury.

The oral presentation at ISHLT2022 of the new PulmoStem™ data, was part of a session presenting novel translational insights in lung transplant complications and care.

*"Lung transplantation is an area of high unmet need. We need both to make more donor lungs suitable for transplantation and to improve the outcome of transplantations. PulmoStem™ addresses both these important needs and my research group, and I, are very encouraged about these data,"* says Professor Sandra Lindstedt at Skåne University Hospital.

*"These very promising data supports PulmoStem™'s ability to regenerate lung tissue and this is important for the PulmoStem™ development program. Lung transplantation has become an increasingly common procedure, but it is lagging behind other transplantations in terms of survival outcomes. Amniotics is committed to helping patients suffering from lung disease, and we are thankful for our collaboration with Sandra and her team,"* says CEO Kåre Engkilde.

### About Lung Transplantation

Lung transplantation is currently the only treatment for patients with end stage lung disease. However, most potential donor lungs are considered unsuitable for transplantation. Once a suitable donor lung is found, a transplantation can be made. Thereafter, the patient undergoes a surgical procedure with the risk of developing PGD, which is a severe lung injury that occurs within the first 72 hours of lung transplantation and is the most common cause of early mortality and co-morbidity. There is currently no treatment to prevent PGD in connection with lung transplantation.

#### About PulmoStem™

PulmoStem™ is a lung-specific stem cell product, derived from full-term amniotic fluid and intended for treatment of lung diseases with inflammatory components like ARDS due to COVID-19 and other causes. PulmoStem™ is also being investigated for treatment of the chronic lung-disease Idiopathic Pulmonary Fibrosis (IPF) and in lung transplantation.

#### For further information, please contact:

---

Kåre Engkilde  
CEO, Amniotics AB  
Phone: +46 (0) 723 27 85 20  
Email: [ke@amniotics.com](mailto:ke@amniotics.com)

Johny Humaloja  
CFO, Amniotics AB  
Phone: +46 (0) 73 506 6856  
Email: [jh@amniotics.com](mailto:jh@amniotics.com)

Amniotics AB (publ) 559024-6558  
Medicon Village,  
Scheelevägen 2, 223 63 Lund, Sweden

#### About Amniotics

---

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se), telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at [www.amniotics.com](http://www.amniotics.com).

Press Release  
28 April 2022 16:00:00 CEST



## Attachments

---

Amniotics AB announces positive pre-clinical proof-of-concept results for PulmoStem™ in end-stage lung disease